The fact that everything looks different doesn't mean that all has changed...
Biblio
Export 7 results:
Author Title Type [ Year
] Filters: Author is Holopainen, Tanja [Clear All Filters]
. CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation. Circulation [Internet]. 2014;129(19). http://circ.ahajournals.org/content/early/2014/02/19/CIRCULATIONAHA.113.002779.abstract
Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (6.6 MB) Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (Suppl.) (2.38 MB) Published version of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated... (incl. suppl.) (23.21 MB)
Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (6.6 MB) Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (Suppl.) (2.38 MB) Published version of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated... (incl. suppl.) (23.21 MB). The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6(282):ra52. Anisimov 2013 Science Signaling (1.92 MB) Anisimov 2013 Science Signaling Supplement (2.09 MB)
Anisimov 2013 Science Signaling (1.92 MB) Anisimov 2013 Science Signaling Supplement (2.09 MB). Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043 Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB) Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB) Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB). Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974 Maija Bry et al., Circulation 2010 (2.23 MB) Maija Bry et al., Circulation 2010, supplement (17.77 MB)
Maija Bry et al., Circulation 2010 (2.23 MB) Maija Bry et al., Circulation 2010, supplement (17.77 MB). The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522 Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
Caroline Heckman et al., Cancer Research 2008 (504.8 KB). Inhibiton of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In 98th Annual Meeting of the American-Association-for-Cancer-Research [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. http://dx.doi.org/10.1158/0008-5472.CAN-07-5809 Heckman et al. - 2007 - Inhibiton of VEGF-C-induced VEGFR-3 activity and l.pdf (236.37 KB)
Heckman et al. - 2007 - Inhibiton of VEGF-C-induced VEGFR-3 activity and l.pdf (236.37 KB). Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292 Yulong He et al., Cancer Research 2005 (1.82 MB)
Yulong He et al., Cancer Research 2005 (1.82 MB)